 |
Mr. Abraham Chan, Founder, Chairman, Chief Executive Officer and Executive Director of PuraPharm (right), receives the "Directors of The Year Awards 2016" from HKIoD. |
HONG KONG, Dec 7, 2016 - (ACN Newswire) - PuraPharm Corporation Limited ("PuraPharm" or the "Group", HKEX: 1498), a leading Hong Kong-based Chinese medicine company specialising in the research and development, production and sale of Concentrated Chinese Medicine Granules ("CCMG") products under the "Nong's" brand, announced that Mr. Abraham Chan, Founder, Chairman, Chief Executive Officer and Executive Director of PuraPharm, has been awarded "Directors of the Year Awards 2016" (Non-Hang Seng Indexes Constituents on SEHK - Executive Directors) by The Hong Kong Institute of Directors ("HKIoD"). The award acknowledges his outstanding performance in leading the Group in business development and also recognises his contribution in enhancing the efficiency of the Board and corporate governance.
The Directors of the Year Awards 2016 is organized by HKIoD, aiming to recognize outstanding boards and directors and promote good corporate governance and professionalism among directors. This year's main theme was "Corporate Sustainability - the Board's Crucial Role." The award winners are selected through a stringent set of procedures. As the first-of-the-kind in Asia, the Directors of the Year Awards has become an annual honors with strong influence in the society.
Mr. Chan said, "We have been emphasizing corporate governance over the years and towards that end we have developed a comprehensive internal control and effective risk management system. I am very honoured to be receiving the award from HKIoD, which not only represents recognition of the Group's excellent corporate governance, but also encourages our efforts in promoting the modernisation and internationalisation of Traditional Chinese Medicine ("TCM"). Of course, this award is also the result of the joint efforts and contributions of the Board and all employees. Apart from promoting the innovation and modernisation of TCM, PuraPharm also strives to achieve better performance through implementing best corporate governance practices. Looking ahead, we will continue to improve our corporate governance standard and remain steadfast in achieving the mission of promoting modernisation and internationalisation of TCM as well as enhancing awareness of the PuraPharm and Nong's brands to capture the huge demand for TCM both within and outside the country."
About PuraPharm Corporation Limited
PuraPharm is a leading Hong Kong-based Chinese medicine company specialising in the research and development, production and sale of CCMG products which the Group markets under its "Nong's" brand. PuraPharm is the largest supplier of CCMG products in Hong Kong with a market share of 70% in terms of prescription revenue for the Hong Kong CCMG product market in 2014, according to the Euromonitor Report. The Group also sells a broad range of general Chinese healthcare products, such as PuraGold and Oncozac, which are essentially Chinese herbal supplements, on an OTC basis, targeting end-consumers. PuraPharm currently operates 50 Nong's clinics in Hog Kong. PuraPharm's shares have been listed on the Main Board of the Stock Exchange of Hong Kong Limited since 8 July 2015 under the stock code 1498.
Contact:
Strategic Financial Relations Limited Heidi So +852 2864 4826 heidi.so@sprg.com.hk Fanny Yuen +852 2864 4853 fanny.yuen@sprg.com.hk Janet Fong +852 2864 4817 janet.fong@sprg.com.hk www.sprg.com.hk
Copyright 2016 ACN Newswire. All rights reserved. www.acnnewswire.com